Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based study

BACKGROUND: Despite approval of azacitidine in 2004 and decitabine in 2006 in the US for chronic myelomonocytic leukemia (CMML), overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS: We selected older adults (age ≥66 years) diagnosed with CMML during 2001–2011 f...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: Zeidan, Amer M., Hu, Xin, Long, Jessica B., Wang, Rong, Ma, Xiaomei, Podoltsev, Nikolai, Huntington, Scott F., Gore, Steven D., Davidoff, Amy J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540984/
https://ncbi.nlm.nih.gov/pubmed/28621841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30814
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk